Rigel Pharmaceuticals
Clinical trials sponsored by Rigel Pharmaceuticals, explained in plain language.
-
New hope for young brain cancer patients: targeted drug combo enters phase 2 trial
Disease control Recruiting nowThis study tests whether adding the drug olutasidenib to standard chemotherapy (temozolomide) can help children and young adults with a specific type of brain cancer (IDH1-mutant high-grade glioma) live longer. About 60 participants will receive the combination as maintenance the…
Phase: PHASE2 • Sponsor: Rigel Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug R289 offers hope for blood disorder patients who failed other therapies
Disease control Recruiting nowThis study tests an experimental drug called R289 in about 86 adults with a type of blood cancer called lower-risk myelodysplastic syndromes (MDS). Participants must have tried other standard treatments without success. The main goal is to check the drug's safety and side effects…
Phase: PHASE1, PHASE2 • Sponsor: Rigel Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New study checks if cancer drug olutasidenib changes how other medicines work
Knowledge-focused Recruiting nowThis study looks at how the cancer drug olutasidenib affects the way the body processes other medications. Researchers will give 16 adults with IDH1-mutated cancers a mix of test drugs before and during olutasidenib treatment to measure changes in drug levels. The goal is to ensu…
Phase: PHASE4 • Sponsor: Rigel Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC